Transcript

Hello, I'm Adam Wolf with the Alliance for Regenerative Medicine, and I'm here with Andrea Snark, the CEO of Inventec here today at Arms Studios. Andreas, welcome. Thank you for being here. Ohh. Thanks so, so much for having me. Awesome. So the first question we want to dive into is automation is of course, a big thing in the Salagen therapy sector today. But first, tell us a little bit about the constraints and bottlenecks we're seeing it in the syngene therapy sector and how automation is really positioned to help these constraints. Yeah, let let me take a step back and say a few words about invitation. Like we are passionate about taking our clients scientific breakthroughs and turning them into commercial realities. Yeah. So especially the scale up is at the core of what we're doing. We're bringing to that lean mindset, the lean methodologies and strategies around about 200 engineers and scientists leave that day-to-day with our clients as we scale up and help make these projects reality. So when when we look at the processes at the moment, we apply. Lean principles and with that you search for the wastes in the processes and, and sadly the way the industry has grown U, it's created tools that at the time were right for, for where the where the automation was needed and, and where the, the therapy developments were happening. As we are now going into the scale up of, of these therapies and are seeing higher numbers of patients, we are reaching the limits of what many of these tools are. Designed for yeah, when you think of some of the tools that you see here around the conference and at the at the various conferences in the space, what it takes to load them, we're trying to mimic that with with robotic automation. Yeah, what what the human does with robotic automation and and it clearly shows that those tools are not designed for the for the full scale of what we believe. So engine will bring for thousands and 10s of thousands of patients. So, so that's, that's where we are right now, I think. All right. Well, you just discussed automation within the cell and gene therapy sector. Describe a little bit some of the ongoing risk with an automation that you guys are trying to solve and could potentially face while trying to help the industry scale up. So, so for obviously when, when you look at the therapy department, the first thing we need to ensure is that we really keep the biology intact with our automation. We need to stay through through the to what the inventors of the of the scientific approach and, and the biology have come up with and maintain that and stabilize their through automation. So our job in the 1st place is consistency and safety for the patient. And and then the next step is with what I was alluding to in the first, in the first question is that we then apply the lean principles to eliminate the waste and always keeping in mind the biology I eat always keeping that stable. So for for us that's that's key. Yeah. So that when when you think of risk and uncertainties, whatever we scale up, that's the point. So we discussed a lot about automation generally within the growth and dynamics of the sector itself. How do you see automatically within Celgene? Therapy is growing and changing over the next 5 to 10 years. I guess for the for the short term, we will live with the technologies and the core unit operations. Instrumentation that that we've got and we will use robotics to load, unload them, make them, make them work in the cleanroom environment the best we can. And that's probably for the next 5 or 10 years of a sufficient answer. I think what we what we're then realizing is that for the scale up we've almost done our inventors at this service because these technologies are as as we already discussed not right for the scalar. So we need to rethink how we design the machines. That I used on the lab bench in the early days of the development that I can use that in a cost efficient manner. And this same core technology needs to be then designed in the way that I can multiply it or scale it up for the later stages, for the high volume stages. And I think that's where where our biggest opportunity is as an industry to create new tools that can cover the whole range in a cost effective manner and and cost obviously is one of our. Biggest inhibit us right now, why don't we, we don't want to introduce more course. We want to take cost out of these therapies. That's our job as technology providers. My second point on that when when to add to the product approach is that very few players alone can make that happen. I think collaboration is key here to drive the right the right approaches to collaboration between science, there is industry partners that come with various strengths and us included. That we come together and maybe create consortia. That sit down and and enable that scale up come with the right degree of investment because these these longer term strategies for technology are not cheap to live out, but it's not impossible. And that's I think why the meeting on the Mesa here and and arms support for us all. It's so important. That's why we're here to find those partnerships and collaborations. We're highly grateful for the partnership we've got with Armenia. Absolutely and we're really grateful to have for you and we're really excited on the future of. In the nation and the role that it'll play insane therapy. And with that, Andreas, it was awesome to have you Arms studios. Thank you very much for joining us. Thanks so much.